ArticleBritish journal of cancer2012
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Upregulation of lnc-FOXD2-AS1, CDC45, and CDK1 in patients with primary non-M3 AML is associated with a worse prognosis.Blood research · 2024Article
- Identification of novel T cell proliferation patterns, potential biomarkers and therapeutic drugs in colorectal cancer.Journal of Cancer · 2024Article
- Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.BMC gastroenterology · 2022Article
- Comprehensive Analysis of Role of Cyclin-Dependent Kinases Family Members in Colorectal Cancer.Frontiers in oncology · 2022Article
- Article
- Expression of cyclin-dependent kinases and their clinical significance with immune infiltrates could predict prognosis in colorectal cancer.Biotechnology reports (Amsterdam, Netherlands) · 2021Article
- Phosphoproteomic Profiling Identifies Aberrant Activation of Integrin Signaling in Aggressive Non-Type Bladder Carcinoma.Journal of clinical medicine · 2019Article
- Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.BMC cancer · 2018Article
- Identification of the potential oncogenes in glioblastoma based on bioinformatic analysis and elucidation of the underlying mechanisms.Oncology reports · 2018Article
- Aberrantly Expressed Genes and miRNAs in Slow Transit Constipation Based on RNA-Seq Analysis.BioMed research international · 2018Article
- Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.Cancer research · 2017Review
- Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer.Oncotarget · 2017Article
- Associating transcriptional modules with colon cancer survival through weighted gene co-expression network analysis.BMC genomics · 2017Article
- Driver gene classification reveals a substantial overrepresentation of tumor suppressors among very large chromatin-regulating proteins.Scientific reports · 2016Article
- Article
- Iron Uptake via DMT1 Integrates Cell Cycle with JAK-STAT3 Signaling to Promote Colorectal Tumorigenesis.Cell metabolism · 2016Article
- Article
- The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.The American journal of pathology · 2015Review
- Targeting cell cycle regulators in hematologic malignancies.Frontiers in cell and developmental biology · 2015Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are no established biomarkers to identify tumour recurrence in stage II colon cancer. As shown previously, the enzymatic activity of the cyclin-dependent kinases 1 and 2 (CDK1 and CDK2) predicts outcome in breast cancer. Therefore, we investigated whether CDK activity identifies tumour recurrence in colon cancer.
methodsIn all, 254 patients with completely resected (R0) UICC stage II colon cancer were analysed retrospectively from two independent cohorts from Munich (Germany) and Leiden (Netherlands). None of the patients received adjuvant treatment. Development of distant metastasis was observed in 27 patients (median follow-up: 86 months). Protein expression and activity of CDKs were measured on fresh-frozen tumour samples.
resultsSpecific activity (SA) of CDK1 (CDK1SA), but not CDK2, significantly predicted distant metastasis (concordance index=0.69, 95% confidence interval (CI): 0.55-0.79, P=0.036). Cutoff derivation by maximum log-rank statistics yielded a threshold of CDK1SA at 11 (SA units, P=0.029). Accordingly, 59% of patients were classified as high-risk (CDK1SA ≥11). Cox proportional hazard analysis revealed CDK1SA as independent prognostic variable (hazard ratio=6.2, 95% CI: 1.44-26.9, P=0.012). Moreover, CKD1SA was significantly elevated in microsatellite-stable tumours.
conclusionSpecific activity of CDK1 is a promising biomarker for metastasis risk in stage II colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.